AIMS/HYPOTHESIS: Inflammation is a common feature in cardiovascular diseases, including diabetes mellitus. In addition to the well-known inflammatory role of cyclo-oxygenase-2 (COX-2), this protein has also been implicated in apoptosis resistance in tumour cells. Vascular smooth muscle cells (VSMC) from diabetic patients are also resistant to apoptosis because of an increased abundance of B cell lymphoma 2 protein (BCL2). In this work, we investigated whether overproduction of COX-2 was involved in the resistance to apoptosis in VSMC from diabetic patients. METHODS: VSMC were obtained from internal mammary arteries from patients who had undergone coronary artery bypass graft surgery. Apoptosis was measured by DNA fragmentation, BCL2 degradation and cytochrome c release. RESULTS: Apoptosis induced by C-reactive protein in cells from non-diabetic patients was mediated by COX-2. VSMC from diabetic patients showed higher basal levels of COX-2 compared with those from non-diabetic patients. Transfection of VSMC from non-diabetic patients with a plasmid containing COX-2 (also known as PTGS2) increased basal production of COX-2 and BCL2 and mimicked the resistance to apoptosis that occurs in diabetic patients. We also found a significant correlation (R = 0.846, p = 0.016) between COX-2 and BCL2 production in arterial rings from diabetic patients measured by confocal microscopy. However, inhibition of COX-2 production by small interfering RNA proved unable to reverse BCL2 production in diabetic VSMC. CONCLUSIONS/ INTERPRETATION: These results suggest a link between inflammation (COX-2) and apoptosis resistance (BCL2) in the arteries of diabetic patients. This relationship is not causative and the common production of these two proteins may be co-regulated by shared regulatory elements in diabetes.
AIMS/HYPOTHESIS: Inflammation is a common feature in cardiovascular diseases, including diabetes mellitus. In addition to the well-known inflammatory role of cyclo-oxygenase-2 (COX-2), this protein has also been implicated in apoptosis resistance in tumour cells. Vascular smooth muscle cells (VSMC) from diabeticpatients are also resistant to apoptosis because of an increased abundance of B cell lymphoma 2 protein (BCL2). In this work, we investigated whether overproduction of COX-2 was involved in the resistance to apoptosis in VSMC from diabeticpatients. METHODS:VSMC were obtained from internal mammary arteries from patients who had undergone coronary artery bypass graft surgery. Apoptosis was measured by DNA fragmentation, BCL2 degradation and cytochrome c release. RESULTS: Apoptosis induced by C-reactive protein in cells from non-diabeticpatients was mediated by COX-2. VSMC from diabeticpatients showed higher basal levels of COX-2 compared with those from non-diabeticpatients. Transfection of VSMC from non-diabeticpatients with a plasmid containing COX-2 (also known as PTGS2) increased basal production of COX-2 and BCL2 and mimicked the resistance to apoptosis that occurs in diabeticpatients. We also found a significant correlation (R = 0.846, p = 0.016) between COX-2 and BCL2 production in arterial rings from diabeticpatients measured by confocal microscopy. However, inhibition of COX-2 production by small interfering RNA proved unable to reverse BCL2 production in diabeticVSMC. CONCLUSIONS/ INTERPRETATION: These results suggest a link between inflammation (COX-2) and apoptosis resistance (BCL2) in the arteries of diabeticpatients. This relationship is not causative and the common production of these two proteins may be co-regulated by shared regulatory elements in diabetes.
Authors: Tamás Szerafin; Nóra Erdei; Tibor Fülöp; Eniko T Pasztor; István Edes; Akos Koller; Zsolt Bagi Journal: Circ Res Date: 2006-08-17 Impact factor: 17.367
Authors: Emilio Ruiz; Antonio Gordillo-Moscoso; Eugenia Padilla; Santiago Redondo; Enrique Rodriguez; Fernando Reguillo; Ana M Briones; Cornelis van Breemen; Elena Okon; Teresa Tejerina Journal: Diabetes Date: 2006-05 Impact factor: 9.461
Authors: F Cipollone; C Prontera; B Pini; M Marini; M Fazia; D De Cesare; A Iezzi; S Ucchino; G Boccoli; V Saba; F Chiarelli; F Cuccurullo; A Mezzetti Journal: Circulation Date: 2001-08-21 Impact factor: 29.690
Authors: Berend Isermann; Ilya A Vinnikov; Thati Madhusudhan; Stefanie Herzog; Muhammed Kashif; Janusch Blautzik; Marcus A F Corat; Martin Zeier; Erwin Blessing; Jun Oh; Bruce Gerlitz; David T Berg; Brian W Grinnell; Triantafyllos Chavakis; Charles T Esmon; Hartmut Weiler; Angelika Bierhaus; Peter P Nawroth Journal: Nat Med Date: 2007-11-04 Impact factor: 53.440
Authors: Florian Blaschke; Dennis Bruemmer; Fen Yin; Yasunori Takata; Wei Wang; Michael C Fishbein; Takafumi Okura; Jitsuo Higaki; Kristof Graf; Eckart Fleck; Willa A Hsueh; Ronald E Law Journal: Circulation Date: 2004-07-26 Impact factor: 29.690
Authors: Antonio Gordillo-Moscoso; Emilio Ruiz; Manuel Carnero; Fernando Reguillo; Enrique Rodriguez; Teresa Tejerina; Santiago Redondo Journal: Lipids Health Dis Date: 2013-05-03 Impact factor: 3.876